First Human Clinical Trials of a Ricin Toxin Vaccine
DOR Biopharma Reports Ricin Vaccine in Phase I Clinical Trial
10-Feb-2005 -
DOR Biopharm announced that DOR and its academic partner began human testing of RiVax(TM), a recombinant vaccine designed to protect against ricin toxin. After having successfully passed prerequisite animal safety and efficacy evaluations, RiVax(TM) (recombinant ricin toxin vaccine) is the first ...
clinical trials
dosing
human antibodies
+3